Acurx Pharmaceuticals (ACXP) Earnings Date, Estimates & Call Transcripts $4.47 -0.18 (-3.87%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.57 +0.10 (+2.24%) As of 08/8/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Acurx Pharmaceuticals Earnings Summary Acurx Pharmaceuticals issued Q1 2025 earnings on May 12, 2025, reporting an EPS of -$2.20, which beat the consensus estimate of -$2.80 by $0.60. With a trailing EPS of -$14.00, Acurx Pharmaceuticals' earnings are expected to decrease next year, from ($0.89) to ($2.06) per share. Upcoming Q2 Earnings DateAug. 12Before Market OpensEstimatedConsensus EPS (May. 12) -$2.80 Actual EPS (May. 12) -$2.20 Beat By $0.60 Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Quarterly Report (10-Q) Press Release (8-K)ACXP Upcoming EarningsAcurx Pharmaceuticals' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2025 Earnings ReportPowered by Get Acurx Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acurx Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataACXP Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Acurx Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$2.80-$2.80-$2.80Q2 20251-$2.00-$2.00-$2.00Q3 20251-$2.20-$2.20-$2.20Q4 20251-$2.40-$2.40-$2.40 Acurx Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/12/2025(Estimated)-------5/12/2025Q1 2025-$2.80-$2.20+$0.60-$0.11--3/17/2025Q4 2024-$3.60-$3.20+$0.40-$0.16--11/12/2024Q3 2024-$4.60-$3.40+$1.20-$0.17--8/9/2024Q2 2024-$5.60-$5.20+$0.40-$0.26--5/14/2024Q1 2024-$4.80-$5.60 -$0.80-$0.28--3/15/2024Q4 2023-$5.20-$7.60 -$2.40-$0.38--11/13/2023Q3 2023-$5.60-$4.80+$0.80-$0.24--8/14/2023Q2 2023-$5.80-$5.60+$0.20-$0.28-- Acurx Pharmaceuticals Earnings - Frequently Asked Questions When is Acurx Pharmaceuticals' earnings date? Acurx Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 12th, 2025 based off last year's report dates. Learn more on ACXP's earnings history. Did Acurx Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Acurx Pharmaceuticals (NASDAQ:ACXP) reported ($2.20) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.80) by $0.60. Learn more on analysts' earnings estimate vs. ACXP's actual earnings. How can I listen to Acurx Pharmaceuticals' earnings conference call? The conference call for Acurx Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Acurx Pharmaceuticals' conference call transcript? The conference call transcript for Acurx Pharmaceuticals' latest earnings report can be read online. Read Transcript How much profit does Acurx Pharmaceuticals generate each year? Acurx Pharmaceuticals (NASDAQ:ACXP) has a recorded net income of -$14.10 million. ACXP has generated -$14.00 earnings per share over the last four quarters. What is Acurx Pharmaceuticals' EPS forecast for next year? Acurx Pharmaceuticals' earnings are expected to decrease from ($0.89) per share to ($2.06) per share in the next year. More Earnings Resources from MarketBeat Related Companies Coeptis Therapeutics Earnings Date LAVA Therapeutics Earnings Date Sol-Gel Technologies Earnings Date Ovid Therapeutics Earnings Date Shattuck Labs Earnings Date Medicus Pharma Earnings Date Enlivex Therapeutics Earnings Date Karyopharm Therapeutics Earnings Date Xilio Therapeutics Earnings Date Rani Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally This page (NASDAQ:ACXP) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
